This drug interaction contraindication for an AD blood test underscores the importance of considering potential confounders, especially in patients with comorbidities, such as for p-tau and kidney disease,6 and suggests that a multibiomarker assessment may better control for factors affecting individual biomarker classes. Here, MAPT is linked to Alzheimer disease.